Global Diabetic Peripheral Neuropathy Market H1 Clinical Trials 2014 Review Research Report Available at RnRMarketResearch.com
Dallas, Texas (PRWEB) May 22, 2014 -- This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy and special features on late-stage and discontinued projects.
“Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2014″ provides data on the Diabetic Peripheral Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Peripheral Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Peripheral Neuropathy.
Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=179159.
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
• Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
• Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
• Listings of discontinued trials (suspended, withdrawn and terminated)
• The report provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy.
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities.
• The report reviews key players involved in the therapeutics development for Diabetic Peripheral Neuropathy and enlists all their major and minor projects.
• The report summarizes all the dormant and discontinued pipeline projects.
• A review of the Diabetic Peripheral Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Diabetic Peripheral Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Complete report available @ http://www.rnrmarketresearch.com/diabetic-peripheral-neuropathy-global-clinical-trials-review-h1-2014-market-report.html.
Reasons to buy
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports on the Clinical Trial industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/clinical-trial.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article